Related references
Note: Only part of the references are listed.Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2023)
Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7
Jonathan I. Silverberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)
Expert consensus on the systemic treatment of atopic dermatitis in special populations
D. N. Adam et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor et al.
ADVANCES IN THERAPY (2023)
Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan
Teppei Hagino et al.
JOURNAL OF DERMATOLOGY (2023)
Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience
Danielle Rogner et al.
ACTA DERMATO-VENEREOLOGICA (2022)
Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials
K. Reich et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis
Cristina Garufi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
The infection risks of JAK inhibition
Maryam A. Adas et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Yoshiya Tanaka et al.
NATURE REVIEWS RHEUMATOLOGY (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
Sheridan M. Hoy
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)
Herpesvirus, serious and opportunistic infections associated with atopic dermatitis
Natalija Novak et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)
Thomas Bieber et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study
Akihiko Uchiyama et al.
JOURNAL OF DERMATOLOGY (2022)
An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis
T. Werfel et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Application of Baricitinib in Dermatology
Jingya Zhang et al.
JOURNAL OF INFLAMMATION RESEARCH (2022)
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
Thomas Bieber et al.
ADVANCES IN THERAPY (2022)
European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
Norito Katoh et al.
DERMATOLOGY AND THERAPY (2022)
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
Celeste M. Boesjes et al.
ACTA DERMATO-VENEREOLOGICA (2022)
New treatments in atopic dermatitis
Neha Puar et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
T. Bieber et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
Brett King et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Baricitinib: From Rheumatoid Arthritis to COVID-19
Sara Assadiasl et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial
A. Wollenberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Atopic Dermatitis
Sonja Staender
NEW ENGLAND JOURNAL OF MEDICINE (2021)
JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials
E. L. Simpson et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial
Kristian Reich et al.
JAMA DERMATOLOGY (2020)
Counting the Burden: Atopic Dermatitis and Health-related Quality of Life
Faraz Ali et al.
ACTA DERMATO-VENEREOLOGICA (2020)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
More than skin deep: the systemic nature of atopic dermatitis
Clara Oliveira et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2019)
Skin diseases associated with atopic dermatitis
Justine Fenner et al.
CLINICS IN DERMATOLOGY (2018)
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Gina A. Montealegre Sanchez et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders
Amy Paller et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)